The GLIS3-AS1 gene, also known as GLIS3 antisense RNA 1, is a long non-coding RNA that has been implicated in various biological processes and disease states. While the provided summaries from NCBI and UniProt may not include extensive details, here is an expanded overview based on available scientific literature and databases:

### 1. Associated Genes
Several genes and genetic loci are known to be associated with GLIS3-AS1, including but not limited to:
- **GLIS3**: As an antisense RNA, GLIS3-AS1 likely regulates GLIS3 expression, which is involved in pancreatic beta-cell function.
- **INS**: Insulin gene regulation is possibly influenced by GLIS3 and its regulatory RNA.
- **KCNJ11**: This gene encodes an ATP-sensitive potassium channel and is often studied in the context of glucose metabolism alongside GLIS3.
- **PRKAA2**: Involved in the AMP-activated protein kinase pathway, relevant for energy balance and metabolism.

These associations are significant as they highlight the potential role of GLIS3-AS1 in metabolic disorders and diabetes.

### 2. Aging and Age-Related Diseases
Recent research suggests that long non-coding RNAs like GLIS3-AS1 may play roles in aging and age-related diseases, particularly:
- **Diabetes**: Since GLIS3 is known for its role in pancreatic function and insulin regulation, GLIS3-AS1 may influence the onset or progression of Type 2 Diabetes Mellitus (T2DM), which is commonly associated with aging.
- **Obesity**: Variants associated with GLIS3 and its regulatory RNA have been linked to obesity, a condition that worsens with age and increases the risk for various age-related diseases.
- **Cancer**: Some studies have investigated the expression of GLIS3-AS1 in various cancers, and aberrant regulation of long non-coding RNAs is often noted in cancer biology.

### 3. Drug Interactions
Direct drug interactions with GLIS3-AS1 specifically may not be well documented in available literature. However, gene regulatory networks may imply interactions through:
- **Antidiabetic drugs**: Drugs such as metformin, which target metabolic pathways, could indirectly affect the expression of GLIS3 or GLIS3-AS1.
- **Epigenetic modulators**: Compounds affecting DNA methylation and histone acetylation may also alter the expression of GLIS3-AS1.

### 4. Pathways and Biological Processes
GLIS3-AS1 is involved in several important biological pathways, including:
- **Metabolic pathways**: Particularly those regulating glucose homeostasis.
- **Insulin signaling pathway**: Involvement in the regulation of insulin expression and activity.
- **Cellular differentiation processes**: Influence on beta-cell differentiation and survival.
- **Regulation of gene expression**: Acting as a molecular sponge or promoter for microRNAs that target associated genes like GLIS3.

### Summary
GLIS3-AS1 is an emerging player in the field of genetics, particularly concerning metabolic processes and age-related diseases. Continued research will likely clarify its roles, mechanisms, and potential therapeutic implications in metabolic diseases and possibly cancer, contributing to our understanding of aging and longevity.